Advertisement

Biology of the Cancer Vaccine Immune Response

  • Michael A. Morse
  • Timothy M. Clay
  • H. Kim Lyerly
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Interest in activating the immune system to control tumors dates to more than 100 yr ago and is often attributed to William B. Coley who used the inflammatory response to bacterial products as a form of immunotherapy (1). This initiated the era of attempts to nonspecifically activate the immune system with the hope that tumors would be targeted as part of the overall, predominantly inflammatory, response. Following the abandonment of the crude bacterial products in Coley’ s toxin, other bacteria or their cell wall products such as bacille Calmette-Guérin (BCG), Corynebacterium parvum, nocardia rubra, OK-432, and others have been tested. In some circumstances, these inflammatory activators have had success as antitumor agents. For example, BCG has activity in superficial bladder cancer in situ (2). Later, cytokines such as interleukin (IL)-2 that could activate T and natural killer (NK) cells were extensively tested and demonstrated activity in renal cell carcinoma and melanoma. In the past two decades, a new era in cancer immunotherapy has opened with the discovery of how the immune system can recognize and destroy tumors. This has included the description of tumor-expressed antigens that can be recognized by immune effectors and a characterization of how immune effectors are primed to recognize these antigens as a signal to destroy the associated tumor. By harnessing these observations, it has been possible to design vaccines with the necessary ingredients for activating tumor antigen-specific immune responses in vivo.

Keywords

Major Histocompatibility Complex Major Histocompatibility Complex Class Tumor Antigen Cancer Vaccine Immune Effector 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Coley WB. The treatment of malignant tumors by repeated inoculation of erysipelas: report of ten original cases. Am J Med Sci 1893; 105:487–511.CrossRefGoogle Scholar
  2. 2.
    Meyer JP, Persad R, Gillatt DA. Use of bacille Calmette-Guerin in superficial bladder cancer. Postgrad Med J 2002; 78:449–454.PubMedCrossRefGoogle Scholar
  3. 3.
    Van Pel A, Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA 1982; 79:4718–4722.PubMedCrossRefGoogle Scholar
  4. 4.
    Abken H, Hombach A, Heuser C, Kronfeld K, Seliger B. Tuning tumor-specific T-cell activation: a matter of costimulation? Trends Immunol 2002; 23:240–245.PubMedCrossRefGoogle Scholar
  5. 5.
    Radaev S, Sun PD. Structure and function of natural killer cell surface receptors. Annu Rev Biophys Biomol Struct 2003; 32:93–114.PubMedCrossRefGoogle Scholar
  6. 6.
    Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 2001; 15:1022–1032.PubMedCrossRefGoogle Scholar
  7. 7.
    Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002; 2:735–747.PubMedCrossRefGoogle Scholar
  8. 8.
    Zeng G. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design. J Immunother 2001; 24:195–204.CrossRefGoogle Scholar
  9. 9.
    Reilly RT, Emens LA, Jaffee EM. Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer? Curr Opin Investig Drugs 2001; 2:133–135.PubMedGoogle Scholar
  10. 10.
    Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, Sumen C, et al. The immunological synapse. Annu Rev Immunol 2001; 19:375–396.PubMedCrossRefGoogle Scholar
  11. 11.
    Brutkiewicz RR, Sriram V. Natural killer T (NKT) cells and their role in antitumor immunity. Crit Rev Oncol Hematol 2002; 41:287–298.PubMedCrossRefGoogle Scholar
  12. 12.
    Gilliet M, Liu YJ. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002; 195:695–704.PubMedCrossRefGoogle Scholar
  13. 13.
    Morse MA, Clay TM, Mosca P, Lyerly HK. Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther 2002; 2:827–834.PubMedCrossRefGoogle Scholar
  14. 14.
    Lee SM, Suen Y, Qian J, Knoppel E, Cairo MS. The regulation and biological activity of interleukin 12. Leuk Lymphoma 1998; 29:427–438.PubMedCrossRefGoogle Scholar
  15. 15.
    Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002; 25:97–138.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2004

Authors and Affiliations

  • Michael A. Morse
  • Timothy M. Clay
  • H. Kim Lyerly

There are no affiliations available

Personalised recommendations